Display options
Cite
Montejano J, Jevtovic-Todorovic V. Anesthesia and Cancer, Friend or Foe? A Narrative Review. Front Oncol. 2021;11:803266doi: 10.3389/fonc.2021.803266.
Montejano, J., & Jevtovic-Todorovic, V. (2021). Anesthesia and Cancer, Friend or Foe? A Narrative Review. Frontiers in oncology, 11803266. https://doi.org/10.3389/fonc.2021.803266
Montejano, Julio, and Jevtovic-Todorovic, Vesna. "Anesthesia and Cancer, Friend or Foe? A Narrative Review." Frontiers in oncology vol. 11 (2021): 803266. doi: https://doi.org/10.3389/fonc.2021.803266
Montejano J, Jevtovic-Todorovic V. Anesthesia and Cancer, Friend or Foe? A Narrative Review. Front Oncol. 2021 Dec 23;11:803266. doi: 10.3389/fonc.2021.803266. eCollection 2021. PMID: 35004329; PMCID: PMC8735748.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 Dec 23;11:803266. doi: 10.3389/fonc.2021.803266. eCollection 2021.

Anesthesia and Cancer, Friend or Foe? A Narrative Review.

Frontiers in oncology

Julio Montejano, Vesna Jevtovic-Todorovic

Affiliations

  1. School of Medicine, University of Colorado, Aurora, CO, United States.

PMID: 35004329 PMCID: PMC8735748 DOI: 10.3389/fonc.2021.803266

Abstract

Cancer remains the leading cause of death worldwide with close to 10 million deaths reported annually. Due to growth of the advanced age cohort in our population, it is predicted that the number of new cancer cases diagnosed between now until 2035 is to reach potentially 24 million individuals, a staggering increase in a relatively short time period. For many solid tumors, surgical resection along with chemotherapy is the best available approach to a potential cure which leads to almost 80% of cancer patients undergoing at least one surgical procedure during the course of their disease. During surgical intervention, the exposure to general anesthesia can be lengthy, complex and often involves various modalities resulting in an important question as to the role, if any, anesthesia may play in primary recurrence or metastatic conversion. Many components of the stress and inflammatory responses exhibited in the perioperative period can contribute to cancer growth and invasion. The agents used to induce and maintain general anesthesia have variable interactions with the immune and neuroendocrine systems and can influence the stress response during surgery. Thus, debating the best type of anesthesia that would help to attenuate sympathetic and/or pro-inflammatory responses while modulating cytokine release and transcription factors/oncogenes remains at the forefront. This may affect inducible cancer cell survival and migratory abilities not only intra-operatively, but also during the immediate post-operative phase of recovery. The ultimate question becomes how and whether the choice of anesthesia may influence the outcomes of cancer surgery with two major approaches being considered, i.e., regional and general anesthesia as well as the various hypnotics, analgesics and sympatholytics commonly used. In this review, we will address the latest information as to the role that anesthesia may play during cancer surgery with specific focus on primary recurrence and metastasis.

Copyright © 2021 Montejano and Jevtovic-Todorovic.

Keywords: cancer recurrence; dexmedetomidine; general anesthesia; lidocaine infusion; metastatic conversion; regional anesthesia; total intravenous anesthesia

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Front Oncol. 2021 Aug 12;11:683232 - PubMed
  2. Onco Targets Ther. 2018 Sep 11;11:5689-5693 - PubMed
  3. Anesthesiology. 2016 Jan;124(1):69-79 - PubMed
  4. Oncol Lett. 2019 Jun;17(6):5517-5522 - PubMed
  5. Medicine (Baltimore). 2019 Nov;98(47):e18088 - PubMed
  6. Cancers (Basel). 2019 Apr 28;11(5): - PubMed
  7. J Anaesthesiol Clin Pharmacol. 2017 Jul-Sep;33(3):317-323 - PubMed
  8. Nature. 2002 Dec 19-26;420(6917):860-7 - PubMed
  9. Cancers (Basel). 2019 May 01;11(5): - PubMed
  10. Pharmacotherapy. 2018 Dec;38(12):1250-1259 - PubMed
  11. Onco Targets Ther. 2018 Jan 03;11:185-191 - PubMed
  12. Drug Des Devel Ther. 2021 Aug 03;15:3379-3390 - PubMed
  13. Can J Anaesth. 2019 May;66(5):546-561 - PubMed
  14. J Pain. 2019 Aug;20(8):980-993 - PubMed
  15. Med Sci Monit. 2019 Jun 23;25:4655-4664 - PubMed
  16. Cancer Prev Res (Phila). 2013 Dec;6(12):1262-72 - PubMed
  17. BMC Anesthesiol. 2019 Dec 18;19(1):233 - PubMed
  18. BMJ Open. 2021 Aug 23;11(8):e048803 - PubMed
  19. Cancer. 2020 Dec 15;126(24):5256-5262 - PubMed
  20. Curr Pharm Des. 2019;25(28):3028-3033 - PubMed
  21. Elife. 2019 Dec 03;8: - PubMed
  22. Drug Des Devel Ther. 2020 Nov 24;14:5155-5166 - PubMed
  23. Cell Syst. 2019 Aug 28;9(2):109-127 - PubMed
  24. Anesth Analg. 2017 May;124(5):1697-1708 - PubMed
  25. Semin Cell Dev Biol. 2019 Aug;92:89-96 - PubMed
  26. Br J Anaesth. 2020 May;124(5):562-570 - PubMed
  27. Cancer Med. 2020 Jun;9(12):4447-4459 - PubMed
  28. Expert Opin Pharmacother. 2019 Jun;20(8):949-961 - PubMed
  29. Horm Mol Biol Clin Investig. 2020 Feb 14;41(3): - PubMed
  30. Exp Mol Med. 2020 Jul;52(7):1062-1074 - PubMed
  31. Br J Anaesth. 2020 Nov;125(5):712-721 - PubMed
  32. BMC Anesthesiol. 2020 Sep 29;20(1):253 - PubMed
  33. Cancer Med. 2019 Dec;8(18):7603-7612 - PubMed
  34. Br J Anaesth. 2014 Jul;113 Suppl 1:i4-13 - PubMed
  35. Int Immunopharmacol. 2020 Jun;83:106388 - PubMed
  36. Eur Rev Med Pharmacol Sci. 2016 Aug;20(16):3500-6 - PubMed
  37. Acta Anaesthesiol Belg. 2015;66(1):1-9 - PubMed
  38. Anticancer Res. 2021 Jun;41(6):2835-2840 - PubMed
  39. J Palliat Med. 2021 Aug;24(8):1154-1160 - PubMed
  40. J Oncol Pharm Pract. 2020 Dec;26(8):1850-1856 - PubMed
  41. Dev Cell. 2008 Jun;14(6):818-29 - PubMed
  42. Gynecol Oncol. 2013 Oct;131(1):15-20 - PubMed
  43. Oncol Lett. 2019 Sep;18(3):3058-3064 - PubMed
  44. Br J Anaesth. 2018 Feb;120(2):368-375 - PubMed
  45. Lancet. 2019 Nov 16;394(10211):1807-1815 - PubMed
  46. Cancer Res. 2017 Sep 1;77(17):4556-4561 - PubMed
  47. Front Immunol. 2019 Dec 12;10:2914 - PubMed
  48. Eur Rev Med Pharmacol Sci. 2018 Jun;22(11):3570-3576 - PubMed
  49. Front Oncol. 2021 Aug 02;11:688896 - PubMed
  50. BMC Anesthesiol. 2018 Sep 22;18(1):131 - PubMed
  51. Per Med. 2019 Nov;16(6):511-525 - PubMed
  52. J Palliat Med. 2019 Mar;22(3):326-334 - PubMed
  53. Minerva Anestesiol. 2021 Feb;87(2):230-237 - PubMed
  54. Br J Anaesth. 2020 Aug;125(2):141-148 - PubMed
  55. Psychiatr Danub. 2019 Mar;31(1):95-101 - PubMed
  56. Biomed Pharmacother. 2021 Oct;142:111991 - PubMed
  57. Oncotarget. 2016 Nov 22;7(47):77087-77095 - PubMed
  58. J Transl Med. 2018 Dec 11;16(1):347 - PubMed
  59. Anesth Analg. 2017 Oct;125(4):1322-1328 - PubMed
  60. Br J Anaesth. 2019 Sep;123(3):335-349 - PubMed
  61. J BUON. 2017 Nov-Dec;22(6):1416-1421 - PubMed
  62. Anesth Analg. 2017 Nov;125(5):1749-1760 - PubMed
  63. Br J Anaesth. 2019 Aug;123(2):135-150 - PubMed
  64. Acta Biochim Biophys Sin (Shanghai). 2018 Feb 1;50(2):156-163 - PubMed
  65. Pharmacogenomics. 2018 Feb;19(3):285-298 - PubMed
  66. Reg Anesth Pain Med. 2017 Nov/Dec;42(6):751-756 - PubMed
  67. Nat Med. 2021 Jan;27(1):34-44 - PubMed
  68. Br J Anaesth. 2018 Jan;120(1):188-196 - PubMed
  69. Cancers (Basel). 2019 Sep 22;11(10): - PubMed
  70. Anticancer Drugs. 2020 Aug;31(7):693-701 - PubMed
  71. J Oncol Pharm Pract. 2014 Oct;20(5):369-80 - PubMed
  72. Exp Ther Med. 2019 Dec;18(6):4820-4828 - PubMed
  73. Clin J Pain. 2021 Feb 1;37(2):126-132 - PubMed
  74. Cochrane Database Syst Rev. 2018 Jun 04;6:CD009642 - PubMed

Publication Types